STOCK TITAN

Paratek Pharmace Stock Price, News & Analysis

PRTK Nasdaq

Welcome to our dedicated page for Paratek Pharmace news (Ticker: PRTK), a resource for investors and traders seeking the latest updates and insights on Paratek Pharmace stock.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical innovator developing advanced therapies for complex infectious diseases. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical research, and strategic initiatives driving antibiotic development.

Key resources include: NUZYRA® treatment advancements, partnership announcements with global health organizations, and progress in addressing antimicrobial resistance. Track updates on pulmonary anthrax preparedness programs and international expansion efforts through our verified news collection.

Discover official communications about Paratek's pipeline developments, including non-tuberculous mycobacterial disease research and antibiotic stewardship programs. All content is sourced from regulatory filings and verified news outlets to ensure reliability for investment analysis and medical research.

Bookmark this page for streamlined access to Paratek's latest achievements in combating life-threatening infections through innovative tetracycline-derived therapies. Check regularly for updates on FDA interactions, European market authorizations, and clinical trial outcomes.

Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options and restricted stock units to three new employees on March 31, 2021. A total of 1,200 stock options were issued at an exercise price of $7.06, vesting over four years. Additionally, 13,800 restricted stock units will vest after 36 months of continuous employment. This move aligns with the 2017 Inducement Plan to attract talent crucial for the company's focus on developing life-saving therapies, including its lead product NUZYRA, an antibiotic for bacterial infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary

On March 01, 2021, Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options and restricted stock units to eight new employees as part of its 2017 Inducement Plan. Stock options total 12,350 shares with an exercise price of $7.48, vesting over four years. Additionally, 3,000 restricted stock units will vest after 36 months. This move aims to attract and retain talent for the company's focus on developing therapies for serious diseases. Paratek's lead product, NUZYRA, is used for treating bacterial infections and is supported by various development agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) reported Q4 2020 revenue of $16 million, a 17% increase from Q3 and 78% year-over-year, driven by NUZYRA's U.S. sales of $12.4 million, up 14% sequentially. The company anticipates 2021 total revenue between $166-177 million, with core NUZYRA sales expected at $138-144 million. Paratek plans to expand NUZYRA into primary care, hiring 40 sales reps for this initiative. The firm reported a net loss of $25 million for Q4, improving from a $27.4 million loss in Q4 2019. For 2021, R&D and SG&A expenses are projected to be approximately $150-155 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. ET. This presentation will provide insights into the company's development of innovative therapies for life-threatening diseases. Investors can access the live webcast here, with a replay available for 90 days post-event. Paratek’s lead product, NUZYRA®, treats bacterial infections, while SEYSARA® focuses on acne treatment. For more details, visit ParatekPharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
-
Rhea-AI Summary

Paratek Pharmaceuticals (PRTK) announced a conference call on February 24, 2021, at 4:30 p.m. EST to discuss its financial results for Q4 and full year 2020. The company focuses on developing novel therapies for life-threatening diseases, with its lead product, NUZYRA, approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections. Paratek has licensing agreements for its products, including NUZYRA and SEYSARA. In 2019, it received a $285 million contract from BARDA for NUZYRA's development and manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
-
Rhea-AI Summary

Paratek Pharmaceuticals is expanding the commercial promotion of NUZYRA into community settings following its successful launch in hospitals. This initiative addresses the critical demand for a once-daily oral antibiotic, particularly during the COVID-19 pandemic. The revenue growth of NUZYRA has outperformed other recent antibiotics, attributed to its effective formulation and broad reimbursement coverage. Paratek plans to hire 40 community-based sales representatives and anticipate a total of 90-100 representatives to enhance awareness and adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options and restricted stock units to 92 new employees on January 29, 2021. Under the 2017 Inducement Plan, these options, totaling 119,650 shares at an exercise price of $6.49, will vest over four years. Additionally, 6,000 restricted stock units will vest after 36 months. Paratek focuses on developing novel therapies for life-threatening diseases, with key products like NUZYRA and SEYSARA. The company retains commercialization rights globally except in specific regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced its participation in the 2021 H.C. Wainwright BIOCONNECT Virtual Conference, set to broadcast on January 11, 2021, at 6:00 a.m. ET. Investors can access the live presentation via a dedicated webcast link. Paratek specializes in developing life-saving therapies for severe diseases, including NUZYRA® (omadacycline) for bacterial infections and SEYSARA® (sarecycline) for acne. The company is also backed by a $285 million BARDA contract to support NUZYRA's development against biothreats.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
conferences
-
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) has announced a $60 million non-recourse loan from R-Bridge Healthcare to prepay its obligations to Hercules Capital. This loan is backed by royalties from its partnership with Zai Lab and U.S. net sales of NUZYRA, with a maturity of 12 years. Paratek expects a $6 million milestone payment from Zai Lab upon regulatory approval in China, anticipated in H1 2021. The loan offers greater financial flexibility, with the option to increase revenue interest rates and caps under specific conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
Rhea-AI Summary

On December 1, 2020, Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options and restricted stock units to a new employee, totaling 6,550 shares. The stock options consist of 3,550 shares at an exercise price of $6.19, with a four-year vesting schedule. The restricted stock units will vest after 36 months. This action adheres to the Paratek 2017 Inducement Plan and aims to incentivize new talent. The company focuses on developing lifesaving therapies, including NUZYRA, an antibiotic for serious infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none

FAQ

What is the market cap of Paratek Pharmace (PRTK)?

The market cap of Paratek Pharmace (PRTK) is approximately 127.8M.
Paratek Pharmace

Nasdaq:PRTK

PRTK Rankings

PRTK Stock Data

127.83M
45.60M
11.7%
55.08%
4.6%
Biotechnology
Healthcare
Link
United States
Boston